Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 218

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

The β‐Lactams Strike Back: Ceftazidime‐Avibactam

Open access
Zasowski, Evan J., Rybak, Jeffrey M., Rybak, Michael J.·2015·Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

Abstract

Gram‐negative resistance has reached a crucial point, with emergence of pathogens resistant to most or all available antibiotics. Ceftazidime‐avibactam is a newly approved agent combining ceftazidime and a novel β‐lactamase inhibitor with activity against multidrug‐resistant gram‐negative bacteria. Avibactam has increased potency and expanded spectrum of inhibition of class A and C β‐lactamases relative to available β‐lactamase inhibitors, including extended‐spectrum β‐lactamases, AmpC, and Klebsiella pneumoniae carbapenemase (KPC) enzymes. Avibactam expands ceftazidime's spectrum of activity to include many ceftazidime‐ and carbapenem‐resistant Enterobacteriaceae and Pseudomonas aeruginosa. Early clinical data indicate that ceftazidime‐avibactam is effective and well tolerated in patients with complicated urinary tract infections (cUTIs) and complicated intraabdominal infections (cIAI). In a phase II trial of patients with cUTIs, ceftazidime‐avibactam produced similar rates of clinical and microbiologic success compared with imipenem‐cilastatin (70.5% and 71.4% microbiologic success rates, respectively). Likewise, patients receiving ceftazidime‐avibactam plus metronidazole in a phase II study of patients with cIAI had similar response rates to those receiving meropenem (91.2% and 93.4% clinical success rates, respectively). Based on available in vitro, in vivo, and phase II trial data, as well as preliminary phase III trial results in ceftazidime‐resistant, gram‐negative cUTI and cIAI, ceftazidime‐avibactam received U.S. Food and Drug Administration approval for treatment of cUTI, including pyelonephritis, and cIAI, in combination with metronidazole, in adult patients with limited or no alternative treatment options. The approved dosage, ceftazidime 2 g–avibactam 0.5 g administered as a 2‐hour infusion every 8 hours, was selected based on pharmacodynamic analysis and available clinical data. This dosage is under further investigation in patients with cUTI, cIAI, and nosocomial or ventilator‐associated pneumonia. The current body of evidence suggests that ceftazidime‐avibactam is a promising addition to our therapeutic armamentarium with potential to answer an urgent unmet medical need. Further data in highly resistant gram‐negative infections, particularly those caused by KPC‐producing Enterobacteriaceae, are needed. As it is introduced into clinical use, careful stewardship and rational use are essential to preserve ceftazidime‐avibactam's potential utility.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/phar.1622

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 218

Metadata

Authors
Zasowski, E. J., Rybak, J. M., & Rybak, M. J.
Venue
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Publisher
Wiley
Published
2015-08
Volume
35
Issue
8
Pages
755-770
ISSN
  • 0277-0008 (ISSN-L)
  • 1875-9114
OpenAlex
W2101004558
Cited by
218
References
1
FWCI
6.89
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.